Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 5, 2003, Pages 1694-1699

  Shelton, Mark J ^a   Hewitt, Ross G ^a,b   Adamse, John ^a,b   Della Coletta, Andrew ^c   Cox, Steven ^c   Morse, Gene D ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b ERIE COUNTY MEDICAL CENTER   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; LAMIVUDINE; RITONAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EXPOSURE; DRUG METABOLISM; DRUG POTENTIATION; EVALUATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PARAMETER; PHARMACOKINETICS; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; DELAVIRDINE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OXIDOREDUCTASES, N-DEMETHYLATING; RITONAVIR;

EID: 0037997003     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.5.1694-1699.2003     Document Type: Article

References (21)

1. Borin, M. T., J. T. Chambers, B. J. Carel, W. W. Freimuth, S. Aksentijevich, and A. A. Piergies. 1997. Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients. Antivir. Res. 35:53-63.
2. Borin, M. T., J. T. Chambers, B. J. Carel, S. Gagnon, and W. W. Freimuth. 1997. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clin. Pharmacol. Ther. 61:544-553.
3. Brockmeyer, N. H., L. Mertins, D. Spatz, I. Tillmann, and M. Goos. 1992. Endogenous interferon plasma levels and antipyrine pharmacokinetics in patients with viral infections. Int. J. Clin. Pharmacol. Ther. Toxicol. 30:530-533.
4. Chen, Y. L., V. LeVraux, A. Leneveu, F. Dreyfus, A. Stheneur, I. Florentin, M. De Sousa, J. P. Giroud, B. Flouvat, and L. Chauvelot-Moachon. 1994. Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin. Pharmacol. Ther. 55:649-660.
5. Cheng, C.-L., D. E. Smith, P. L. Carver, S. R. Cox, P. B. Watkins, D. S. Blake, C. A. Kauffman, K. M. Meyer, G. L. Amidon, and P. L. Stetson. 1997. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. Clin. Pharmacol. Ther. 61:531-543.
6. Eagling, V. A., D. J. Back, and M. G. Barry. 1997. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br. J. Clin. Pharmacol. 44(2):190-194.
7. Ferry, J. J., B. D. Herman, B. J. Carel, G. F. Carlson, and D. H. Batts. 1998. Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 18:252-259.
8. Fletcher, C. V., E. P. Acosta, H. Cheng, R. Haubrich, M. Fischl, R. Raasch, C. Mills, X. J. Hu, D. Katzenstein, R. P. Remmel, R. M. Gulick, and the ACTG Protocol Team. 2000. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884. AIDS 14:2495-2501.
9. Friedland, G. H., R. Pollard, B. Griffith, M. Hughes, G. Morse, R. Bassett, W. Freimuth, L. Demeter, E. Connick, T. Nevin, M. Hirsch, and M. Fischl. 1999. Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). J. Acquir. Immune Defic. Syndr. 21:281-292.
10. a.Hoetelmans, R. M., M. van Essenberg, M. Profijt, P. L. Meenhorst, J. W. Mulder, and J. H. Beijnen. 1998. High-performance liquid chromatographic determination of ritonavir in human plasma, cerebrospinal fluid and saliva. J. Chromatogr. B 705:119-126.
11. Hsu, A., G. R. Granneman, G. Witt, C. Locke, J. Denissen, and A. Molla. 1997. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 41:898-905.
12. Kumar, G. N., A. D. Rodrigues, A. M. Buko, and J. F. Denissen. 1996. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther. 277(1):423-431.
13. Lee, B. L., D. Wong, N. L. Benowitz, and P. M. Sullam. 1993. Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin. Pharmacol. Ther. 53:529-535.
14. Merry, C., M. G. Barry, F. Mulcahy, M. Ryan, J. Heavey, J. F. Tijia, K. L. Halifax, J. Heavey, C. Kelly, and D. J. Back. 1997. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS II:F29-F33.
15. Morse, G. D., M. A. Fischl, S. R. Cox, L. Thompson, A. A. Della-Coletta, and W. W. Freimuth. 2003. Effect of food on the steady-state pharmacokinetics of delavirdine mesylate in HIV+ patients. Clin. Drug Investig. 23:255-261.
16. Nokta, M., J. P. Loh, S. M. Douidar, A. E. Ahmed, and R. B. Pollard. 1991. Metabolic interaction of recombinant interferon-β and zidovudine in AIDS patients. J. Interferon Res. 11:159-164.
17. Okumo, H., Y. Kitao, M. Takasu, H. Kano, K. Kunieda, and T. Seki. 1990. Depression of drug metabolizing activity in the human liver by interferon-α. Eur. J. Clin. Pharmacol. 39:365-367.
18. Ouellet, D., A. Hsu, G. R. Granneman, G. Carlson, J. Cavanaugh, H. Guenther, and J. M. Leonard. 1998. Pharmacokinetic interaction between ritonavir and clarithromycin. Clin. Pharmacol. Ther. 64:355-362.
19. Ouellet, D., A. Hsu, J. Qian, J. E. Lamm, J. H. Cavanaugh, J. M. Leonard, and G. R. Granneman. 1998. Effect of fluoxetine on pharmacokinetics of ritonavir. Antimicrob. Agents Chemother. 42:3107-3112.
20. Piscitelli, S., D. Rock-Kress, R. Bertz, A. Pau, and R. Davey. 2000. The effect of ritonavir on the pharmacokinetics of meperidine and normeperidine. Pharmacotherapy 20:549-553.
21. Voorman, R. L., S. M. Maio, N. A. Payne, Z. Zhao, K. A. Koeplinger, and X. Wang. 1998. Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A. J. Pharmacol. Exp. Ther. 287:381-388.